Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

sight sciences inc - SGHT

SGHT

Close Chg Chg %
9.05 -0.23 -2.54%

Closed Market

8.82

-0.23 (2.54%)

Volume: 216.77K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: sight sciences inc - SGHT

SGHT Key Data

Open

$9.06

 Day Range

8.75 - 9.24

52 Week Range

2.03 - 9.24

 Market Cap

$478.49M

Shares Outstanding

52.87M

 Public Float

28.38M

Beta

2.41

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.90

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

254.25K

  

SGHT Performance

1 Week
 
 4.38%
 
1 Month
 
 5.50%
 
3 Months
 
 153.45%
 
1 Year
 
 147.06%
 
5 Years
 
 N/A
 

SGHT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About sight sciences inc - SGHT

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

SGHT At a Glance

Sight Sciences, Inc.
4040 Campbell Avenue
Menlo Park, California 94025
Phone 1-877-266-1144 Revenue 79.87M
Industry Medical Specialties Net Income -51,507,000.00
Sector Health Technology Employees 216
Fiscal Year-end 12 / 2025
View SEC Filings

SGHT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.285
Price to Book Ratio 2.118
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.057
Enterprise Value to Sales 1.283
Total Debt to Enterprise Value 0.394

SGHT Efficiency

Revenue/Employee 369,750.00
Income Per Employee -238,458.333
Receivables Turnover 7.405
Total Asset Turnover 0.516

SGHT Liquidity

Current Ratio 9.036
Quick Ratio 8.627
Cash Ratio 7.781

SGHT Profitability

Gross Margin 85.499
Operating Margin -63.271
Pretax Margin -64.196
Net Margin -64.492
Return on Assets -33.285
Return on Equity -49.588
Return on Total Capital -40.276
Return on Invested Capital -36.766

SGHT Capital Structure

Total Debt to Total Equity 46.116
Total Debt to Total Capital 31.561
Total Debt to Total Assets 28.257
Long-Term Debt to Equity 45.507
Long-Term Debt to Total Capital 31.144
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sight Sciences Inc - SGHT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
48.96M 71.33M 81.06M 79.87M
Sales Growth
+77.12% +45.70% +13.63% -1.47%
Cost of Goods Sold (COGS) incl D&A
8.61M 12.36M 11.88M 11.58M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.20M 1.25M 614.00K 712.00K
Depreciation
1.20M 1.25M 614.00K 712.00K
Amortization of Intangibles
- - - -
-
COGS Growth
-7.51% +43.57% -3.88% -2.53%
Gross Income
40.35M 58.97M 69.17M 68.28M
Gross Income Growth
+120.10% +46.16% +17.31% -1.29%
Gross Profit Margin
+82.41% +82.67% +85.34% +85.50%
2021 2022 2023 2024 5-year trend
SG&A Expense
91.82M 142.92M 126.45M 118.82M
Research & Development
15.63M 22.86M 17.56M 17.99M
Other SG&A
76.19M 120.06M 108.89M 100.83M
SGA Growth
+74.18% +55.65% -11.53% -6.04%
Other Operating Expense
- - - -
-
Unusual Expense
- - 6.86M 1.96M
-
EBIT after Unusual Expense
(58.34M) (83.95M) (57.27M) (52.49M)
Non Operating Income/Expense
(67.00K) 2.23M 7.25M 5.88M
Non-Operating Interest Income
- - - 5.92M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.37M 4.47M 5.41M 4.66M
Interest Expense Growth
+81.69% +2.29% +21.09% -13.79%
Gross Interest Expense
4.37M 4.47M 5.41M 4.66M
Interest Capitalized
- - - -
-
Pretax Income
(62.77M) (86.19M) (55.44M) (51.27M)
Pretax Income Growth
-81.25% -37.31% +35.68% +7.51%
Pretax Margin
-128.22% -120.84% -68.39% -64.20%
Income Tax
188.00K 47.00K 110.00K 236.00K
Income Tax - Current - Domestic
- - - 172.00K
-
Income Tax - Current - Foreign
16.00K 47.00K 110.00K 236.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(62.96M) (86.24M) (55.55M) (51.51M)
Minority Interest Expense
- - - -
-
Net Income
(62.96M) (86.24M) (55.55M) (51.51M)
Net Income Growth
-81.48% -36.98% +35.59% +7.27%
Net Margin Growth
-128.61% -120.90% -68.53% -64.49%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(62.96M) (86.24M) (55.55M) (51.51M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(62.96M) (86.24M) (55.55M) (51.51M)
EPS (Basic)
-1.3253 -1.8024 -1.1423 -1.0274
EPS (Basic) Growth
-78.66% -36.00% +36.62% +10.06%
Basic Shares Outstanding
47.50M 47.85M 48.63M 50.13M
EPS (Diluted)
-1.3253 -1.8024 -1.1423 -1.0274
EPS (Diluted) Growth
-78.66% -36.00% +36.62% +10.06%
Diluted Shares Outstanding
47.50M 47.85M 48.63M 50.13M
EBITDA
(50.28M) (82.70M) (56.66M) (49.82M)
EBITDA Growth
-51.11% -64.49% +31.49% +12.07%
EBITDA Margin
-102.70% -115.94% -69.90% -62.38%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 7.85
Number of Ratings 7 Current Quarters Estimate -0.153
FY Report Date 12 / 2025 Current Year's Estimate -0.739
Last Quarter’s Earnings -0.16 Median PE on CY Estimate N/A
Year Ago Earnings -1.03 Next Fiscal Year Estimate -0.609
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 7 7
Mean Estimate -0.15 -0.17 -0.74 -0.61
High Estimates -0.09 -0.07 -0.50 -0.32
Low Estimate -0.24 -0.25 -0.90 -0.96
Coefficient of Variance -37.22 -43.99 -22.91 -39.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Sight Sciences Inc - SGHT

Date Name Shares Transaction Value
Mar 14, 2025 Paul Badawi President and CEO; Director 6,034,754 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 Allegro Investment, Inc. Director 4,693,920 Other acquisition or disposition Non-derivative transaction at $2.53 per share 11,875,617.60
Mar 14, 2025 Allegro Investment, Inc. Director 4,843,920 Other acquisition or disposition Non-derivative transaction at $2.71 per share 13,127,023.20
Mar 14, 2025 Allegro Investment, Inc. Director 5,086,920 Other acquisition or disposition Non-derivative transaction at $2.77 per share 14,090,768.40
Mar 14, 2025 Matthew W. Link Chief Commercial Officer 835,593 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 David Y. Badawi Chief Technology Officer; Director 1,842,684 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 Alison K. Bauerlein Chief Financial Officer 669,191 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 Jeremy Hayden Chief Legal Officer 284,876 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 MK Raheja EVP, Research & Development 135,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 14, 2025 MK Raheja EVP, Research & Development 145,000 Open market or private purchase of non-derivative security Non-derivative transaction at $2.72 per share 394,400.00
Mar 14, 2025 MK Raheja EVP, Research & Development 155,000 Open market or private purchase of non-derivative security Non-derivative transaction at $2.6 per share 403,000.00

Sight Sciences Inc in the News